FDA approves first gene therapy for genetic hearing loss
FDA, genetik işitme kaybı için ilk gen terapisini (Otarmeni) onayladı. Regeneron tarafından geliştirilen tedavi, kalıtsal işitme kaybına karşı yeni bir tedavi seçeneği sunuyor.
The U.S. Food and Drug Administration has authorized the first gene therapy aimed at treating genetic hearing loss. This groundbreaking treatment, developed by Regeneron and named Otarmeni, offers a new therapeutic avenue for individuals affected by certain inherited forms of deafness.
The approval marks a significant advancement in the field of otology and genetic medicine, potentially providing hope for improved hearing outcomes in patients who previously had limited treatment options.
This approval represents a major milestone in treating genetic hearing loss, offering a novel therapeutic approach for a condition with few existing interventions.
📌 Kaynak
Bu özet nbcnews kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →